Vimarsana
Biggest News Aggregation in the World

Page 22 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma - Vimarsana News

BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Superior overall survival for tislelizumab plus chemotherapy versus chemotherapy in first-line treatment setting ... | April 20, 2023

BeiGene, Ltd. (NASDAQ:BGNE) Given Average Rating of "Moderate Buy" by Analysts - Vimarsana News

BeiGene, Ltd. (NASDAQ:BGNE) Given Average Rating of "Moderate Buy" by Analysts

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) has been given an average rating of “Moderate Buy” by the nine brokerages that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have […]

Source: wkrb13.com
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023 - Vimarsana News

MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

MapKure, LLC, BeiGene, Ltd. , and SpringWorks Therapeutics, Inc. , today announced that they will present updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational, selective... | April 17, 2023

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023 - Vimarsana News

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

BeiGene, Ltd. , and SpringWorks Therapeutics, Inc. , today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in... | April 17, 2023

The FDA Is Resuming Inspections of Drugmakers in China. - Vimarsana News

The FDA Is Resuming Inspections of Drugmakers in China.

China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.